Assenagon Asset Management S.A. Has $18.09 Million Holdings in CryoPort, Inc. $CYRX

Key Points

• Assenagon Asset Management cut its CryoPort stake by 23% in the second quarter, selling 343,372 shares and retaining 1.15 million shares worth approximately $18.1 million. Institutional investors collectively own 92.9% of the company.
• Analysts remain broadly positive on CryoPort: seven analysts rate the stock a Buy and two rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $18.
• CryoPort reported quarterly revenue of $49.0 million, slightly above expectations, but its $0.20-per-share loss missed estimates by $0.01. Meanwhile, insiders sold 227,641 shares worth roughly $3.6 million over the past three months.

Assenagon Asset Management S.A. decreased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 23.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,152,311 shares of the company's stock after selling 343,372 shares during the period. Assenagon Asset Management S.A. owned approximately 2.29% of CryoPort worth $18,091,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Basepoint Wealth LLC acquired a new stake in CryoPort in the 4th quarter valued at $34,000. Tower Research Capital LLC TRC grew its stake in CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock valued at $44,000 after purchasing an additional 4,375 shares in the last quarter. Creative Planning bought a new position in CryoPort in the second quarter valued at approximately $96,000. Quadrature Capital Ltd acquired a new position in shares of CryoPort during the 4th quarter worth approximately $97,000. Finally, State of Wyoming increased its position in shares of CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company's stock worth $106,000 after purchasing an additional 3,301 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CYRX shares. Craig Hallum lifted their price objective on shares of CryoPort from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, June 3rd. Weiss Ratings restated a "hold (c-)" rating on shares of CryoPort in a research report on Monday, August 3rd. Guggenheim boosted their price objective on shares of CryoPort from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday. KeyCorp boosted their price target on CryoPort from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Wednesday, May 20th. Finally, Needham & Company LLC raised their price objective on shares of CryoPort from $15.00 to $19.00 and gave the company a "buy" rating in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

CryoPort Price Performance

NASDAQ CYRX opened at $15.12 on Monday. CryoPort, Inc. has a 52 week low of $7.51 and a 52 week high of $16.89. The business has a 50 day moving average price of $15.49 and a 200-day moving average price of $11.92. The company has a market cap of $765.83 million, a price-to-earnings ratio of -16.80 and a beta of 1.89.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The firm had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. On average, equities research analysts anticipate that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Insider Buying and Selling at CryoPort

In related news, Director Ramkumar Mandalam sold 23,214 shares of the company's stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the sale, the director owned 67,894 shares of the company's stock, valued at approximately $1,048,283.36. This represents a 25.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Edward J. Zecchini sold 33,600 shares of CryoPort stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the sale, the insider owned 109,719 shares of the company's stock, valued at approximately $1,587,633.93. This trade represents a 23.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 227,641 shares of company stock valued at $3,622,515 over the last three months. 9.50% of the stock is currently owned by insiders.

More CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source